High vaccine effectiveness persists for ten years after HPV16/18 vaccination among young Dutch women

Vaccine. 2023 Jan 9;41(2):285-289. doi: 10.1016/j.vaccine.2022.11.057. Epub 2022 Dec 2.

Abstract

The current study describes the long-term effectiveness of three-dose HPV16/18 vaccination among Dutch women who were eligible for vaccination during a catch-up campaign and were followed in an observational cohort study. Ten years post vaccination, vaccine effectiveness (VE) was estimated using generalized estimating equation models. VE against persistent infections with vaccine type infections (HPV16/18) was high at 95.8%. For cross protective type persistent infections (HPV31/33/45) this was 64.6%. There were no indications of waning of protection over time. This indicates solid long-term protection is provided by the vaccine and is promising with regard to the future clinical impact.

Keywords: Human papillomavirus; Observational study; Vaccine effectiveness.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Human papillomavirus 16
  • Human papillomavirus 18
  • Humans
  • Papillomavirus Infections* / prevention & control
  • Papillomavirus Vaccines*
  • Persistent Infection
  • Uterine Cervical Neoplasms* / prevention & control
  • Vaccination
  • Vaccine Efficacy

Substances

  • Papillomavirus Vaccines